Armata Price To Sales Ratio from 2010 to 2025
ARMP Stock | USD 1.84 0.05 2.79% |
Price To Sales Ratio | First Reported 2010-12-31 | Previous Quarter 29.68 | Current Value 28.2 | Quarterly Volatility 31.2 K |
Check Armata Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Armata Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.1 M, Interest Expense of 11.3 M or Selling General Administrative of 12.5 M, as well as many indicators such as Price To Sales Ratio of 28.2, Days Sales Outstanding of 256 or Invested Capital of 0.0. Armata financial statements analysis is a perfect complement when working with Armata Pharmaceuticals Valuation or Volatility modules.
Armata | Price To Sales Ratio |
Latest Armata Pharmaceuticals' Price To Sales Ratio Growth Pattern
Below is the plot of the Price To Sales Ratio of Armata Pharmaceuticals over the last few years. Price to Sales Ratio is figured by comparing Armata Pharmaceuticals stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Armata Pharmaceuticals sales, a figure that is much harder to manipulate than other Armata Pharmaceuticals multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. It is a valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period. Armata Pharmaceuticals' Price To Sales Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Armata Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
View | Last Reported 12.18 X | 10 Years Trend |
|
Price To Sales Ratio |
Timeline |
Armata Price To Sales Ratio Regression Statistics
Arithmetic Mean | 7,851 | |
Geometric Mean | 57.13 | |
Coefficient Of Variation | 397.65 | |
Mean Deviation | 14,634 | |
Median | 45.34 | |
Standard Deviation | 31,219 | |
Sample Variance | 974.6M | |
Range | 124.9K | |
R-Value | (0.42) | |
Mean Square Error | 859.6M | |
R-Squared | 0.18 | |
Significance | 0.10 | |
Slope | (2,757) | |
Total Sum of Squares | 14.6B |
Armata Price To Sales Ratio History
About Armata Pharmaceuticals Financial Statements
Armata Pharmaceuticals shareholders use historical fundamental indicators, such as Price To Sales Ratio, to determine how well the company is positioned to perform in the future. Although Armata Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Armata Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Armata Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last Reported | Projected for Next Year | ||
Price To Sales Ratio | 29.68 | 28.20 |
Additional Tools for Armata Stock Analysis
When running Armata Pharmaceuticals' price analysis, check to measure Armata Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Armata Pharmaceuticals is operating at the current time. Most of Armata Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Armata Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Armata Pharmaceuticals' price. Additionally, you may evaluate how the addition of Armata Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.